Loading
TT
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) Stock: price and insider trades · Canada
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.): what insiders have been doing
This page follows insider dealings at Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) as filed with SEDI. Nothing new has been filed by managers of Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) in twelve months, the latest record being from 31 August 2017.
Our records for Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) go back to 2016, with 11 purchases and no sales on the open market in total.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
13
Thresholds
n/a
Buy Volume
€410,869
11 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 31 August 2017
Declarations13 total
10,640 shares@ CA$4.621612.0% of flowCommon SharesTSXSEDI:3052362
Canonical exit: 26 Nov 2017 (T+90)
2,100 shares@ CA$5.6011.6% of flowCommon SharesTSXSEDI:3048963
Canonical exit: 15 Nov 2017 (T+90)
2,200 shares@ CA$5.5512.1% of flowCommon SharesTSXSEDI:3049133
Canonical exit: 19 Nov 2017 (T+90)
700 shares@ CA$5.653.9% of flowCommon SharesTSXSEDI:3048418
Canonical exit: 15 Nov 2017 (T+90)
4,000 shares@ CA$5.61622.2% of flowCommon SharesTSXSEDI:3048417
Canonical exit: 14 Nov 2017 (T+90)
3,000 shares@ CA$7.88149.0% of flowCommon SharesTSXSEDI:2932326
Canonical exit: 23 Mar 2017 (T+90)
10,000 shares@ CA$6.230518.6% of flowCommon SharesTSXSEDI:2926769
Canonical exit: 12 Mar 2017 (T+90)
3,000 shares@ CA$8.07651.0% of flowCommon SharesTSXSEDI:2926323
Canonical exit: 12 Mar 2017 (T+90)
Common SharesTSXSEDI:2926321
9,224 shares@ CA$10.8428.3% of flowCommon SharesTSXSEDI:2839679
Canonical exit: 16 Aug 2016 (T+90)
Common SharesTSXSEDI:2810869
9,000 shares@ CA$11.114100.0% of flowCommon SharesTSXSEDI:2810862
Canonical exit: 20 Jun 2016 (T+90)
23,020 shares@ CA$8.2153.1% of flowCommon SharesTSXSEDI:2810870
Canonical exit: 19 Jun 2016 (T+90)
13 of 13 declarations
About Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.)
Trillium Therapeutics Inc. is a biopharmaceutical company focused on developing innovative treatments for cancer. Formerly known as Stem Cell Therapeutics Corp., it is listed on the XTSE.
